By analysing tissues, cell cultures and bodily fluids, we identify and characterise the biochemical causes of various functional deficiencies as well as conditions of disease and health. Modern academic pharmacology develops new principles and points of approach for the drug treatments of the future and increases understanding of how current drugs work.

Division representative: Magnus Abrahamson 046-222 16 48

Clinical genetics covers research into the roles played by inherited and acquired genetic mutations for the onset of various forms of cancer and congenital hereditary diseases. Our research is focused on different aspects of cancer genetics and cancer biology. This includes the identification and characterization of cancer-associated genetic aberrations, investigations of the functional outcome of somatic mutations, and the development of novel targeted therapies for various forms of cancer.

Division representative: Kajsa Paulsson 046-222 69 95

We study the blood and immune system and its diseases. A particular focus area is how congenital genetic variation affects blood and immune cells, and how such variation can be utilized clinically. Which genes and gene mutations control, for example, the risk of blood cancer? Can we use them to prevent and treat? Who controls our blood group set? Can we use them for safer transfusion? Another important focus area is clinical trials of new drugs for blood cancer diseases.

Division representative: Björn Nilsson, 046-222 07 38

Lund Stem Cell Center (SCC) is a world-leading virtual center for stem cell research with the mission of transferring basic science findings to the clinic in order to make a fundamental difference to improve human health.

Coordinator of Stem Cell Center: Johan Jakobsson 046-222 42 25
 

We address how the host response determines if infections cause disease or asymptomatic bacterial carriage and novel immune response strategies that can be used therapeutically to strengthen the immune response to replace or complement antibiotics. In addition we have discovered a new cancer therapeutic (HAMLET) and investigate the structure, function and therapeutic efficacy of this molecule.

Division representative: Gabriela Godaly, 0733 381 344

We conduct research into the blood cells’ function and maturity in health and disease by using patient material, animal models as well as cell and molecular biology.

Division representative: David Bryder 046-222 39 51

We investigate the properties of blood stem cells and develop cell and gene therapies for various blood diseases – including genetic diseases and cancer.

Division representative: Jonas Larsson, 046-222 05 80

We research how people’s work and environment condition their health, focusing on metals, environmental toxins, carcinogenic substances and substances which damage the respiratory tract, stress and work-related musculoskeletal disorders, as well as the elderly in working life. Our strength is a combination of register studies and biobanks, field studies and experimental studies.

Division representative: Lars Rylander, 046-222 16 31

Our task is to understand the basic mechanisms behind tumour development. This understanding provides a basis for matching the right drug with the right patient and thereby offer better conditions for individualised treatment of cancer patients.

Division representative: Ramin Massoumi, 046-222 64 30